Skip to main content
Signal8

ThermoGenesis Holdings, Inc. (THMO)

ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.

Sector: Medical - Devices

Industry: Medical - Devices

ThermoGenesis Holdings, Inc. logo

ThermoGenesis Holdings, Inc.

OTC:THMOHealthcare
CLOSED
Mkt Cap$2K
EV-
Float3.51M
O/S15.85M
VOL2K sh
$ Vol$0
RVOL0.54×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsNov 17 · Today
Dilution
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 3.51M · FMP free float

345
Oct 30 (18d)prev 345– 0.0%
1.00
Oct 30 (18d)prev 24.64▼ 95.9%
Borrow (IBKR)

The cost to borrow THMO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 2026345 sh
Oct 15, 2026345 sh
Sep 30, 2026345 sh
Sep 15, 2026345 sh
Aug 31, 2026345 sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

FINRA publishes no off-exchange short volume for this symbol.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for THMO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 345 THMO shares were sold short (0.01% of a 3.51M-share float, 1.00 days to cover).